10:31 AM EDT, 08/06/2024 (MT Newswires) -- Bicycle Therapeutics ( BCYC ) reported Q2 net loss Tuesday of $0.77 per diluted share, narrowing from a loss of $1.41 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.12.

Revenue for the quarter fell to $9.36 million from $11.4 million a year ago.

Analysts polled by Capital IQ expected $6.3 million.

Cash and cash equivalents as of June 30 totaled $961.4 million, compared with $526.4 million as of Dec. 31, 2023. The company said the funds would extend its financial runway into H2 of 2027.

Price: 22.24, Change: -0.47, Percent Change: -2.07